NEW YORK (GenomeWeb News) – Gamida For Life Group has acquired electronic microarray technologies from the Elitech Group, a private group of in vitro diagnostics and reagent companies, for an undisclosed sum, Elitech said today.

Paris-based Elitech said that the intellectual property and tangible assets Gamida bought was from Epoch Bioscience, part of Elitech's Wescor division, and were originally acquired from Nanogen in July, 2009, for $25.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.